Microhealth (YC S15) — Rare Disease-Focused care delivery and evidence generation platform
* Category leading RWE platform generating differentiated data through combination of a provider community and patient-reported outcomes; delivering personalized and comparative evidence at the point of care * Singular network architecture and data capturing capabilities help identify patients with unmet needs in real-time; unlocking opportunities to improve health outcomes and additional revenue for pharma * Microhealth has achieved product-market fit in the hemophilia and rare blood disorders space Today, we are the world's leader in digital hematology: - Our US hemophilia network covers 33%+ of patients on prophylaxis and 50%+ of hemophilia treatment centers - Average active-user retention is 52 months - Trusted by leading pharmaceutical sponsors: Novo Nordisk, Sanofi, Roche and Pfizer
Microhealth is a Y Combinator company in the Summer 2015 batch. Its directory entry describes it as: Rare Disease-Focused Care Delivery and Evidence Generation Platform. The founders listed are Miguel Lara (Founder/CEO), Marc Lara (Founder) (Y Combinator directory entry, April 27, 2015).
Get an email when Microhealth changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
* Category leading RWE platform generating differentiated data through combination of a provider community and patient-reported outcomes; delivering personalized and comparative evidence at the point of care
* Singular network architecture and data capturing capabilities help identify patients with unmet needs in real-time; unlocking opportunities to improve health outcomes and additional revenue for pharma
* Microhealth has achieved product-market fit in the hemophilia and rare blood disorders space
Today, we are the world's leader in digital hematology:
- Our US hemophilia network covers 33%+ of patients on prophylaxis and 50%+ of hemophilia treatment centers
- Average active-user retention is 52 months
- Trusted by leading pharmaceutical sponsors: Novo Nordisk, Sanofi, Roche and Pfizer
Miguel Lara
Founder/CEO
Marc Lara
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 119 companies held here in Healthcare › Consumer Health and Wellness.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Microhealth?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Microhealth: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Microhealth covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Microhealth: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
